ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease

Lecanemab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that preferentially targets soluble aggregated Aβ species (protofibrils) with activity at amyloid plaques. Amyloid‐related imaging abnormalities (ARIA) profiles appear to differ for various anti‐amyloid antibodies. Here, we present ARIA data from a large phase 2 lecanemab trial (Study 201) in early Alzheimer's disease.

[1]  F. Barkhof,et al.  Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease , 2022, The Journal of Prevention of Alzheimer's Disease.

[2]  F. Lombardo,et al.  Safety and Efficacy of Monoclonal Antibodies for Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials , 2022, Journal of Alzheimer's disease : JAD.

[3]  J. Suhy,et al.  Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer’s Disease Treated with Anti-Amyloid Beta Therapy , 2022, The Journal of Prevention of Alzheimer's Disease.

[4]  A. Falini,et al.  Amyloid-Related Imaging Abnormalities and β-Amyloid-Targeting Antibodies: A Systematic Review. , 2022, JAMA neurology.

[5]  F. Barkhof,et al.  Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease , 2021, JAMA neurology.

[6]  P. Scheltens,et al.  Aducanumab: Appropriate Use Recommendations , 2021, The Journal of Prevention of Alzheimer's Disease.

[7]  M. Mintun,et al.  Donanemab in Early Alzheimer's Disease. , 2021, The New England journal of medicine.

[8]  D. Berry,et al.  A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody , 2020, Alzheimer's Research & Therapy.

[9]  Matheus B. Victor,et al.  Reconstruction of the human blood–brain barrier in vitro reveals a pathogenic mechanism of APOE4 in pericytes , 2020, Nature Medicine.

[10]  S. Haeberlein,et al.  Aducanumab 36-month data from PRIME: a randomized, double-blind, placebo-controlled Phase 1b study in patients with prodromal or mild Alzheimer’s disease (S2.004) , 2018 .

[11]  M. Mintun,et al.  Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease , 2018, The New England journal of medicine.

[12]  G. Eslick,et al.  Safety and Efficacy of Anti-Amyloid-β Immunotherapy in Alzheimer’s Disease: A Systematic Review and Meta-Analysis , 2016, Journal of Neuroimmune Pharmacology.

[13]  K. Rhodes,et al.  The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease , 2016, Nature.

[14]  Donald A. Berry,et al.  Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease , 2016, Alzheimer's & dementia.

[15]  E. Liu,et al.  A Randomized, Double-Blind, Phase 2 Study of the Effects of the Vaccine Vanutide Cridificar with QS-21 Adjuvant on Immunogenicity, Safety and Amyloid Imaging in Patients with Mild to Moderate Alzheimer's Disease. , 2016, The journal of prevention of Alzheimer's disease.

[16]  B. Winblad,et al.  Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer’s disease , 2015, Alzheimer's Research & Therapy.

[17]  L. Lannfelt,et al.  The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. , 2014, Journal of Alzheimer's disease : JAD.

[18]  J. Ringman,et al.  Clinical predictors of severe cerebral amyloid angiopathy and influence of APOE genotype in persons with pathologically verified Alzheimer disease. , 2014, JAMA neurology.

[19]  E. Siemers,et al.  Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.

[20]  G. Antoni,et al.  Specific uptake of an amyloid-β protofibril-binding antibody-tracer in AβPP transgenic mouse brain. , 2013, Journal of Alzheimer's disease : JAD.

[21]  Nick C Fox,et al.  Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis , 2012, The Lancet Neurology.

[22]  F. Nikolajeff,et al.  Large Aggregates Are the Major Soluble Aβ Species in AD Brain Fractionated with Density Gradient Ultracentrifugation , 2012, PloS one.

[23]  F. Barkhof,et al.  Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. , 2012, Archives of neurology.

[24]  Clifford R. Jack,et al.  Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup , 2011, Alzheimer's & Dementia.

[25]  Dag Sehlin,et al.  Heavy-Chain Complementarity-Determining Regions Determine Conformation Selectivity of Anti-Aβ Antibodies , 2010, Neurodegenerative Diseases.

[26]  Brad J Kolls,et al.  A PHASE 2 MULTIPLE ASCENDING DOSE TRIAL OF BAPINEUZUMAB IN MILD TO MODERATE ALZHEIMER DISEASE , 2010, Neurology.

[27]  R. Sperling,et al.  A Single Ascending Dose Study of Bapineuzumab in Patients With Alzheimer Disease , 2010, Alzheimer disease and associated disorders.

[28]  Nick C Fox,et al.  11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study , 2010, The Lancet Neurology.

[29]  L. Lannfelt,et al.  An amyloid-β protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease , 2009, Neurobiology of Disease.

[30]  Dag Sehlin,et al.  Sensitive ELISA detection of amyloid‐β protofibrils in biological samples , 2007 .

[31]  L. Lannfelt,et al.  Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. , 2007, Journal of neurochemistry.

[32]  R O Weller,et al.  Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. , 1998, The American journal of pathology.